Zdrowie i gospodarka · 06/06/2016
FDA Clears APRESOLINE (Hydralazine Hydrochloride) Injectable and Other Drug Products for Sale
The US Food and Drug Administration (FDA) has ruled that APRESOLINE (Hydralazine Hydrochloride) Injectable and other listed drug products were not withdrawn from sale due to safety or effectiveness concerns, allowing the FDA to continue approving abbreviated new drug applications (ANDAs) for these products.